LEI:
549300Q7EXQQH6KF7Z84
14 February
2024
RTW Biotech Opportunities
Ltd
Monthly Valuation Update, January
Factsheet
+2.5% NAV movement for the
month
RTW Biotech Opportunities Ltd (the
"Company" or "RTW Bio") announces that the unaudited
net asset value attributable to the ordinary shares of the Company
(the "NAV") at the close of
business on 31 January 2024 was US$407.1 million, or US$1.94 per
ordinary share, +2.5% from the previous month.
The monthly factsheet
is available on the Company's website:
https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
It is important to note that this NAV and
January Factsheet do not reflect the completion of the Arix
Bioscience plc ("Arix")
transaction (the "Transaction"), which closed after
January month-end with the new RTW Bio shares being admitted to
trading on 13 February 2024. It does, however, include the
previously announced acquisition of a 25.5% stake in Arix for a
total consideration of US$57.1 million (representing £1.37 per Arix
share) as reported on 22 January. On 31 January, the Arix stake
amounted to 13.7% of NAV and was held in the "other public" segment
of the portfolio, and as such it is not shown on the January
Factsheet, which only shows core positions.
The Company
intends to publish, at the soonest opportunity, an indicative and
estimated pro forma NAV and NAV per share as at the closing date of
the Transaction, reflecting the completion of the Transaction and
new share issuance.
For
Further Information:
RTW
Investments, LP
|
+44
20 7959 6361
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
ir@rtwfunds.com
|
|
|
Buchanan (PR & Communications Adviser)
|
+44
20 7466 5107
|
Charles Ryland
|
|
Henry Wilson
|
|
George Beale
|
|
|
|
Deutsche Numis (Joint Corporate Broker)
|
+44
20 7260 1000
|
Freddie Barnfield
|
|
Nathan Brown
|
|
Euan Brown
|
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
Edward Peel
|
|
Alex Penney
|
|
Cadarn Capital (Distribution & IR
Partner)
|
+44
73 6888 3211
|
David Harris
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44
(0) 14 8181 0100
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.